stockportfolio.pro
Intellia Therapeutics, Inc. (NTLA)
Healthcare · Biotechnology · NasdaqGM
Intellia Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.48M | $26.12M | $30.43M | $43.10M | $57.99M | $33.05M | $52.12M | $36.27M | $57.88M | $67.67M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-31.63M | $-67.54M | $-85.34M | $-474.19M | $-134.23M | $-267.89M | $-474.19M | $-481.19M | $-519.02M | $-412.69M |
| Net margin | -192.0% | -258.6% | -280.4% | -1100.1% | -231.5% | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% |
Source: Intellia Therapeutics, Inc. SEC filings (10-K). 11 years of history available in the interactive view.
Explore 11 years of Intellia Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track NTLA in your portfolio →
Intellia Therapeutics, Inc. financial history by metric
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Intellia Therapeutics, Inc. — frequently asked questions
What is Intellia Therapeutics, Inc.'s revenue?
Intellia Therapeutics, Inc. (NTLA) reported revenue of $67.67M for fiscal year 2025, up 16.9% from the prior year, according to its SEC filings.
Is Intellia Therapeutics, Inc. profitable?
No — NTLA reported a net loss of $-412.69M in fiscal 2025.
What is NTLA's P/E ratio?
Intellia Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Intellia Therapeutics, Inc. growing?
NTLA's revenue grew at roughly 3.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Intellia Therapeutics, Inc. have?
As of fiscal year 2025, NTLA carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Intellia Therapeutics, Inc.'s market cap?
Intellia Therapeutics, Inc. (NTLA) has a market capitalization of about $1.69B, based on the latest data in our nightly-refreshed cache.
When does Intellia Therapeutics, Inc.'s fiscal year end?
NTLA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Intellia Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 11 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.